Paris (ots/PRNewswire) – YERVOY (ipilimumab) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with previously-treated unresectable or metastatic melanoma. The European Commission will consider the CHMP’s positive opinion in its decision on whether to grant a Marketing Authorisation by August 2011. “Despite the rising [...]
Tag Archive > Bristol Myers Squibb
/C O R R E C T I O N — Bristol-Myers Squibb and AstraZeneca/
Paris and London (ots/PRNewswire) – In the news release, “ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe” issued on 4 Mar 2011 08:00 GMT, by Bristol-Myers Squibb and AstraZeneca NYSE:AZN over PR Newswire, we would like to advise that the headline was incorrectly transmitted by PR Newswire and should have read “ONGLYZA(R) [...]
ONGLYZA(R) Becomes the First DPP-4 Inhibitor Available for Use in Europe
Paris and London (ots/PRNewswire) – Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca.com) today announced that the European Commission has approved a label update for ONGLYZA(R) (saxagliptin) in the treatment of adults with type 2 diabetes who have moderate or severe renal impairment. The approved dosage for the patient group is a new once-daily 2.5 mg [...]
BARACLUDE(R) (entecavir) Approved by the European Commission for the Treatment of Chronic Hepatitis B in Adult Patients With Evidence of Decompensated Liver Disease
Paris (ots/PRNewswire) – Bristol-Myers Squibb announced today that BARACLUDE(R) (entecavir) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B (CHB) in adult patients with evidence of decompensated liver disease. BARACLUDE(r) was already approved in Europe in June 2006 for use in adult patients with CHB with compensated liver [...]
European Approval for SPRYCEL(R) (dasatinib) in Adult Patients With Newly Diagnosed CML: First New Approved Treatment in the E.U. With Superior Efficacy vs. Imatinib Since 2001
Paris (ots/PRNewswire) – Bristol-Myers Squibb today announced that SPRYCEL(R) (dasatinib) 100mg once daily received Marketing Authorization from the European Commission for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukaemia in Chronic Phase (CML-CP). Sprycel is the first new approved treatment in the E.U. with superior efficacy vs. imatinib [...]
Follow-Up Results from Study Comparing SPRYCEL(R) (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data[1]
Princeton, New Jersey and Tokyo (ots/PRNewswire) – Bristol-Myers Squibb Company (http://www.bms.com) and Otsuka Pharmaceutical Co., Ltd. today announced 18-month follow-up results from the Phase 3 DASISION study of SPRYCEL(R) (dasatinib) 100 mg once daily vs. imatinib (400 mg daily) in the first-line treatment of adults with Philadelphia chromosome-positive (Ph+) chronic phase chronic myeloid leukemia (CP-CML). [...]
SPRYCEL(R) (dasatinib) Receives CHMP Positive Opinion for the Treatment of Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukaemia in Chronic Phase
Paris (ots/PRNewswire) – Bristol-Myers Squibb today announced that SPRYCEL(r) (dasatinib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive Chronic Myelogenous Leukaemia in Chronic Phase (CML-CP). This decision follows the presentation of results from the pivotal DASISION study [...]
Accera, Inc. ernennt Dr. Thomas Werner zum Präsidenten & Vorstandsvorsitzenden und gibt FDA-Akzeptanz von IND-Anwendung für AC-1204 für leichten bis mittelschweren Alzheimer bekannt
Broomfield, Colorado (ots/PRNewswire) – Accera, Inc., ein Unternehmen für medizinische Forschung und Entwicklung, das bahnbrechende Therapien für schwerwiegende Erkrankungen wie Alzheimer (AD) bereitstellt, gab heute bekannt, dass Thomas Werner, Ph.D., zum Präsidenten und Vorstandsvorsitzenden ernannt wurde. Zeitgleich mit Dr. Werners Ernennung hat die US-amerikanische Zulassungsbehörde “Food and Drug Administration” (FDA) Acceras Bewerbung um ein “Investigational [...]
24-Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin (HbA1c) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus
Stockholm (ots/PRNewswire) – Bristol-Myers Squibb Company (http://www.bms.com) and AstraZeneca (http://www.astrazeneca-us.com) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride [...]
ScaleUp Technologies ernennt Scott Sanchez zum Beauftragten für Datenschutz und Sicherheit / Der Cloud Computing Provider gründet einen Sicherheitsbeirat, um Cloud Computing vertrauenswürdiger zu machen
Hamburg (ots) – ScaleUp Technologies, der europäische Vorreiter für cloud-basierte Datacenter Infrastrukturen, gibt die Ernennung von Scott Sanchez zum Beauftragten für Datenschutz und Sicherheit bekannt. Sanchez ist ein anerkannter Vordenker und Referent für Datenschutz im Cloud Computing-Bereich. Sehr oft erkennen Unternehmensleitungen den geschäftlichen Nutzen des Cloud Computing und sehen, dass es einen erheblichen Return on [...]
Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin
Orlando, Florida, June 26, 2010 (ots/PRNewswire) – Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c), in inadequately controlled type 2 diabetes patients who were treated with insulin (with or without oral anti-diabetes medications (OADs)), compared to [...]
52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added To Metformin Was Non-Inferior To Titrated Glipizide When Added To Metformin In Reducing Glycosylated Hemoglobin (HbA1c) In Adults With Type 2 Diabetes Mellitus
Orlando, Florida, June 26, 2010 (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca today announced results from a 52-week Phase 3b study in adults with type 2 diabetes who had inadequate glycemic control on metformin therapy plus diet and exercise. This study found that the addition of ONGLYZA(TM) (saxagliptin) 5 mg to existing metformin therapy achieved [...]
ONGLYZA(TM) (saxagliptin) With Metformin As Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control In Treatment-Naive Adults With Type 2 Diabetes
Orlando, Florida, June 26, 2010 (ots/PRNewswire) – Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement [as measured by glycosylated hemoglobin level (HbA1c)] in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on [...]
Fleishman-Hillard gewinnt zwei Sabre Awards für Kampagnen in Frankreich und dem Mittleren Osten / Europäische Agentur des Jahres 2009
Frankfurt/Main (ots) – Die PR-Agentur Fleishman-Hillard wurde Ende Mai in London für zwei Kampagnen mit den europäischen Sabre Awards ausgezeichnet. Die Hepatitis-B-Awarenesskampagne für Bristol-Myers Squibb gewann als beste französische PR-Kampagne, die Arbeiten für die King Abdullah University of Science and Technology (KAUST) siegten in der Länderkategorie Türkei / Mittlerer Osten Neben diesen Einzelauszeichnungen wurde Fleishman-Hillard [...]
"Leben vor Pharmaprofit! Patente können tödlich sein." / Pharmakonzerne nehmen Protestnote und Forderungen entgegen
Tübingen/Berlin (ots) – Zum diesjährigen Welt-Aids-Tag am 1. Dezember wird das Aktionsbündnis gegen AIDS mit einer symbolischen Aktion lebenswichtige Aids-Medikamente aus dem Würgegriff der Patente befreien. Gelingen kann dies allerdings nur, wenn Pharmakonzerne ihre Patentpolitik grundlegend ändern. Wenn am kommenden Dienstag auf dem Berliner Hausvogteiplatz Medikamentenkapseln in den Berliner Himmel aufsteigen, werden VertreterInnen der Pharmakonzerne [...]
